Correction: Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Correction: Impact of Timing for Adjuvant Chemotherapy Following Cytoreductive Surgery on Survival in Epithelial Ovarian Cancer: A Retrospective Cohort Analysis
To correct the placement of figures and clarify the patient selection process in the study on adjuvant chemotherapy timing after cytoreductive surgery in epithelial ovarian cancer.
Approach:
Study Design: A retrospective cohort study was conducted involving patients treated at Nottingham University Hospitals who underwent maximal-effort cytoreductive surgery for epithelial ovarian, fallopian tube, or primary peritoneal cancer from January 2016 to December 2021.
Patient Selection: Eligible patients had histologically confirmed cancers and received primary or interval cytoreductive surgery followed by adjuvant platinum-based chemotherapy. Exclusions included secondary surgeries for recurrent disease and non-epithelial tumors.
Key Findings:
Figure 1 was incorrectly placed in the Methods section and should be in the Results section.
The Flow Diagram for patient selection was omitted and the corresponding sentence in the Methods section was removed.
Interpretation:
The corrections clarify the methodology and presentation of results in the study.
Limitations:
The study is limited to a single institution, which may affect the generalizability of the findings.
The retrospective nature may introduce biases in patient selection and data interpretation.
Conclusion:
The article has been updated to correct figure placements and clarify the patient selection process.
